Literature DB >> 16280337

Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?

Stephen C L Gough1, Michael C O'Donovan.   

Abstract

People with schizophrenia are more likely to develop type 2 diabetes than the general population. Although an increased risk of diabetes has been attributed to environmental determinants such as diet, lifestyle and antipsychotic drugs, the association between these two disorders was noticed well before the advent of current lifestyles and pharmacological interventions, raising the possibility of a shared genetic basis. Schizophrenia and type 2 diabetes are common diseases with a complex mode of inheritance which includes both genetic factors and environmental determinants. As susceptibility genes for both type 2 diabetes and schizophrenia are beginning to be identified there is increasing interest in the possibility of shared susceptibility loci between the two conditions. This article reviews the genetic basis to schizophrenia and type 2 diabetes and discusses the potential for shared loci between both conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280337     DOI: 10.1177/0269881105058380

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  27 in total

1.  A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis.

Authors:  Christine L McKibbin; Shahrokh Golshan; Kathryn Griver; Katherine Kitchen; Thomas L Wykes
Journal:  Schizophr Res       Date:  2010-08       Impact factor: 4.939

Review 2.  Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Authors:  Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Parental history of type 2 diabetes in patients with nonaffective psychosis.

Authors:  Emilio Fernandez-Egea; Brian Miller; Miguel Bernardo; Thomas Donner; Brian Kirkpatrick
Journal:  Schizophr Res       Date:  2007-11-26       Impact factor: 4.939

4.  Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders.

Authors:  Suraj Sarvode Mothi; Neeraj Tandon; Jaya Padmanabhan; Ian T Mathew; Brett Clementz; Carol Tamminga; Godfrey Pearlson; John Sweeney; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2015-04-19       Impact factor: 4.939

5.  Glucose abnormalities in the siblings of people with schizophrenia.

Authors:  Emilio Fernandez-Egea; Miguel Bernardo; Eduard Parellada; Azucena Justicia; Clemente Garcia-Rizo; Enric Esmatjes; Ignacio Conget; Brian Kirkpatrick
Journal:  Schizophr Res       Date:  2008-06-02       Impact factor: 4.939

Review 6.  Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

Authors:  Emilio Sacchetti; Cesare Turrina; Paolo Valsecchi
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

Review 7.  Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.

Authors:  Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-06       Impact factor: 3.568

8.  Serious mental illness and medical comorbidities: Findings from an integrated health care system.

Authors:  Amber L Bahorik; Derek D Satre; Andrea H Kline-Simon; Constance M Weisner; Cynthia I Campbell
Journal:  J Psychosom Res       Date:  2017-07-08       Impact factor: 3.006

9.  Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Authors:  Jaana Suvisaari; Jonna Perälä; Samuli I Saarni; Tommi Härkänen; Sami Pirkola; Matti Joukamaa; Seppo Koskinen; Jouko Lönnqvist; Antti Reunanen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

Review 10.  Lipid effects of psychiatric medications.

Authors:  Junzo Watanabe; Yutaro Suzuki; Toshiyuki Someya
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.